Forty Seven
Palo Alto
About Forty Seven
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $156.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2019)
- Ticker: nasdaq:FTSV
- Website: fortyseveninc.com
- Phone: 650-352-4150
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/forty-seven-140511 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.